CryoLife Announces On-X Aortic Heart Valve PROACT Study Results to be Presented at American Association for Thoracic Surgery Centennial Meeting

ATLANTA, April 27, 2017 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that results from the On-X aortic heart valve PROACT study will be presented in a late-breaking session at the American Association for Thoracic Surgery (AATS) Centennial Meeting, which is being held April 29 to May 3, 2017 at the Hynes Convention Center in Boston, MA.

Study Title: A Prospective Trial of Anticoagulation and Antiplatelet Strategies After Mechanical Aortic Valve Replacement (PROACT)

Presenter: PROACT study principal investigator, John D. Puskas, MD, Professor of Surgery, Icahn School of Medicine at Mount Sinai and Chairman, Department of Cardiovascular Surgery, Mount Sinai Saint Luke's

Session Date/Time: Tuesday, May 2, 2017 from 12:45 – 2:00 PM EDT

About CryoLife

Headquartered in suburban Atlanta, Georgia, CryoLife is a leader in the manufacturing, processing, and distribution of implantable living tissues and medical devices used in cardiac surgical procedures.  CryoLife markets and sells products in more than 80 countries worldwide.  For additional information about CryoLife, visit our website, www.cryolife.com.

Contacts:

SOURCE CryoLife, Inc.

Related Links

http://www.cryolife.com